Spero Therapeutics Stock (NASDAQ:SPRO), Trade Ideas

Spero Therapeutics

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RGLS

RMBL

SPRB

SPRO

TCON

UNCY

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

BBAI

HOVR

MNMD

Shares of  Robinhood Markets, Inc. (NASDAQ: HOOD) rose sharply in today’s pre-market trading after the company reported February trading metrics.

Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Broad U.S. Equity ETFs

Exclusives

Tech

ETFs

AAPL

ADTX

AMZN

ATXI

BBBY

MSFT

NRBO

NVDA

SAVA

SHPH

TSLA

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

EXCLUSIVE: Top 10 Stocks Searched On Benzinga Pro In September: Where Do Tesla, Apple, Bed Bath &amp; Beyond Rank?

Spero Therapeutics Inc

Sprott Copper Miners ETF

Sprott ESG Gold ETF

Sprott Energy Transition Materials ETF

Sprott Focus Trust, Inc. - Closed End Fund

Sprott Focus Trust Inc

Sprott Gold Miners ETF

Sprott Inc

Sprott Junior Copper Miners ETF

Sprott Junior Gold Miners ETF

Sprott Junior Uranium Miners ETF

Sprott Lithium Miners ETF

Sprott Nickel Miners ETF

Sprott Physical Gold Trust

Sprott Physical Gold and Silver Trust Units

Sprott Physical Gold and Silver Trust

Sprott Physical Platinum and Palladium Trust

Sprott Physical Platinum & Palladium Tr

Sprott Physical Silver Trust

Sprott Physical Uranium Trust

Sprott Uranium Miners ETF

Sprout AI Inc

Sprout Social, Inc - Class A Common Stock

Sprout Social Inc

SPROUT TINY HOMES by Sprout Tiny Homes, Inc.

Sprout Tiny Homes Inc

Sproutly Canada Inc

Sprouts Farmers Market, Inc. - Common Stock

Sprouts Farmers Market Inc

Cantor Fitzgerald analyst Louise Chen reiterates Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Spero Therapeutics

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) with a Buy and maintains $7 price target.

Price Target

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target

Shares of Limbach Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmb#NASDAQ">LMB</a>) fell sharply during Thursday&rsquo;s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Limbach said it sees FY24 revenue of $510 million to $530 million, versus market estimates of $541.1 million.
Limbach shares dipped 14.7% to $42.42 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Aptorum Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apm#NASDAQ">APM</a>) shares climbed 91% to $8.27.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) shares jumped 65.2% to $0.3715 after jumping 15% on Wednesday.</li>
<li>Cheer Holding, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chr#NASDAQ">CHR</a>) surged 43.3% to $3.77 following full year 2023 financial results.</li>
<li>WiMi Hologram Cloud Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wimi#NASDAQ">WIMI</a>) shares gained 36.9% to $1.5060.</li>
<li>Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) gained 29.2% to $14.25 after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.</li>
<li>VAALCO Energy, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/egy#NYSE">EGY</a>) rose 22% to $5.45 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Build-A-Bear Workshop, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbw#NYSE">BBW</a>) gained 15.7% to $29.20 after the company reported better-than-expected fourth-quarter EPS but missed on revenue. Additionally, the company guided FY24 revenue growth on a low-to-mid-single-digit percentage basis.</li>
<li>Unicycive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uncy#NASDAQ">UNCY</a>) gained 15% to $1.5980. The company announced a $50 million private placement.</li>
<li>DICK&#39;S Sporting Goods, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dks#NYSE">DKS</a>) rose 14.8% to $215.70 after the company reported strong fourth-quarter results and issued guidance above consensus estimates.</li>
<li>Lithium Americas Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lac#NYSE">LAC</a>) surged 14.6% to $6.57 after the company announced that it received a conditional commitment from the U.S. Department of Energy for a $2.26 billion loan under the Advanced Technology Vehicles Manufacturing Loan Program for financing the construction of the processing facilities at Thacker Pass in Nevada.</li>
<li>Auddia Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auud#NASDAQ">AUUD</a>) shares gained 11.5% to $3.07 after falling 6% on Wednesday.</li>
<li>Impinj, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pi#NASDAQ">PI</a>) gained 11.5% to $126.53 after the company announced a patent litigation settlement with NXP Semiconductors.</li>
<li>ShiftPixy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pixy#NASDAQ">PIXY</a>) gained 9.2% to $3.5501 after gaining over 3% on Wednesday.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) rose 8.7% to $3.6401 after gaining 14% on Wednesday.</li>
<li>Eventbrite, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/eb#NYSE">EB</a>) surged 8.7% to $5.55. Eventbrite announced a $100 million share repurchase program.</li>
<li>Perfect Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/perf#NYSE">PERF</a>) gained 8.6% to $2.8550.</li>
<li>Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) rose 6.3% to $18.24 after the company reported February trading metrics.</li>
<li>Spero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spro#NASDAQ">SPRO</a>) climbed 5.1% to $1.7450 following better-than-expected fourth-quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) shares dipped 78.5% to $1.1150 after the company reported FY23 financial results. Also, the company announced that the CAHmedlia-203 study of Tildacerfont in adult classic congenital adrenal hyperplasia with severe hyperandrogenemia did not meet its primary efficacy endpoint.</li>
<li>Better Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bttx#NASDAQ">BTTX</a>) tumbled 78% to $0.0452. Better Therapeutics announced it will seek strategic alternatives and will be delisted from the Nasdaq.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 49% to $0.1644 following a Wall Street Journal report suggesting the company is preparing for a possible bankruptcy filing.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) dipped 33.7% to $0.4182.</li>
<li>Immuneering Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrx#NASDAQ">IMRX</a>) fell 31.6% to $4.02 after the company announced topline results from Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in RAS-mutant solid tumors.</li>
<li>RCM Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcmt#NASDAQ">RCMT</a>) dipped 27.9% to $20.74 following weak quarterly sales.</li>
<li>Katapult Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kplt#NASDAQ">KPLT</a>) declined 27% to $13.44 following fourth-quarter results.</li>
<li>Hello Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/momo#NASDAQ">MOMO</a>) fell 24.1% to $5.82 after the company reported fourth-quarter financial results and issued first-quarter revenue guidance.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) dipped 23.8% to $4.9750. First Wave BioPharma announcec completion of business combination with ImmunogenX.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) declined 22.5% to $12.02 after the company commenced an underwritten offering of 6.5 million shares.</li>
<li>RumbleON, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmbl#NASDAQ">RMBL</a>) fell 21.8% to $5.55 following weak quarterly sales.</li>
<li>Pangaea Logistics Solutions, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/panl#NASDAQ">PANL</a>) dipped 20% to $6.62 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Regulus Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgls#NASDAQ">RGLS</a>) tumbled 16.9% to $2.0188.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/woof#NASDAQ">WOOF</a>) fell 16.4% to $2.1050. Baird analyst Justin Kleber maintained Petco Health and Wellness with a Neutral and lowered the price target from $3 to $2.5.</li>
<li>G-III Apparel Group, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/giii#NASDAQ">GIII</a>) fell 16.3% to $25.37 following mixed fourth-quarter financial results. The company also issued lower-than-expected revenue and EPS guidance for FY25.</li>
<li>NextNav Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nn#NASDAQ">NN</a>) fell 15% to $4.7640 after posting a quarterly loss.</li>
<li>SentinelOne, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/s#NYSE">S</a>) dipped 14.9% to $23.78 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Erayak Power Solution Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/raya#NASDAQ">RAYA</a>) fell 14.5% to $0.8025 after surging 31% on Wednesday.</li>
<li>Global Gas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hgas#NASDAQ">HGAS</a>) shares fell 13.3% to $2.15 after surging 16% on Wednesday.</li>
<li>Sunnova Energy International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) declined 12.8% to $4.0540.</li>
<li>Highest Performances Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/puyi#NASDAQ">PUYI</a>) dipped 12.6% to $7.47.</li>
<li>Under Armour, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uaa#NYSE">UAA</a>) dipped 12.6% to $7.07 amid volatility following a CEO transition. Additionally, Williams Trading downgraded the stock from Buy to Hold and announced an $8 price target.</li>
<li>Vroom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrm#NASDAQ">VRM</a>) shares tumbled 11.2% to $15.53 as the company reported a loss of $80.51 per share for the fourth quarter. The company&rsquo;s quarterly sales came in at $235.92 million which beat the analyst consensus estimate of $232 million.</li>
<li>Futu Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/futu#NASDAQ">FUTU</a>) shares fell 9.5% to $59.17 following fourth-quarter results.</li>
<li>Madrigal Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdgl#NASDAQ">MDGL</a>) fell 9.1% to $248.09.</li>
<li>Qilian International Holding Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qli#NASDAQ">QLI</a>) shares tumbled 8.8% to $0.5921 after surging 18% on Wednesday.</li>
<li>Affirm Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afrm#NASDAQ">AFRM</a>) fell 8.3% to $35.56.</li>
<li>UiPath Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/path#NYSE">PATH</a>) fell 6.8% to $22.72 after the company reported fourth-quarter financial results.</li>
<li>Anheuser-Busch InBev SA/NV (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bud#NYSE">BUD</a>) shares fell 4.7% to $61.51 after Altria announced its intent to sell a portion of its investment in the company.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37701714/ethereum-falls-below-4-000-following-ppi-data-bittensor-apecoin-among-top-losers"> Ethereum Falls Below $4,000 Following PPI Data; Bittensor, ApeCoin Among Top Losers </a>

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Shares of Robinhood Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) rose sharply in today&rsquo;s pre-market trading after the company reported February trading metrics.
After the market close on Wednesday, Robinhood said total funded customers grew to 23.6 million at the end of February, up approximately 130,000 from January.
Robinhood Markets shares jumped 11.6% to $19.15in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>ShiftPixy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pixy#NASDAQ">PIXY</a>) gained 50.4% to $4.89 in pre-market trading after gaining over 3% on Wednesday.</li>
<li>Presto Automation Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prst#NASDAQ">PRST</a>) shares rose 39.6% to $0.3140 in pre-market trading after jumping 15% on Wednesday.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cctg#NASDAQ">CCTG</a>) rose 29.9% to $4.35 in pre-market trading after gaining 14% on Wednesday.</li>
<li>Turtle Beach Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hear#NASDAQ">HEAR</a>) gained 23.5% to $13.64 in pre-market trading after the company announced the acquisition of PDP and its intention to launch a modified &quot;Dutch Auction&quot; Tender Offer. The company also reported fourth-quarter financial results.</li>
<li>Spero Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spro#NASDAQ">SPRO</a>) climbed 18.1% to $1.96 in pre-market trading following better-than-expected fourth-quarter financial results.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hovr#NASDAQ">HOVR</a>) shares gained 18.1% to $3.12 in pre-market trading after adding around 10% on Wednesday.</li>
<li>BigBear.ai Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NASDAQ">BBAI</a>) gained 13.3% to $2.79 in pre-market trading after gaining over 5% on Wednesday. BigBear.Ai recently reported worse-than-expected fourth-quarter financial results.</li>
<li>Mind Medicine (MindMed) Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnmd#NASDAQ">MNMD</a>) rose 13.2% to $9.73 in pre-market trading after gaining 9% on Wednesday.</li>
<li>Auddia Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auud#NASDAQ">AUUD</a>) shares gained 13.1% to $3.11 in pre-market trading after falling 6% on Wednesday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sprb#NASDAQ">SPRB</a>) fell 74.2% to $1.34 pre-market trading after reporting FY23 results. The company also announced resource prioritization and cost reductions including reduction in force of 21%.</li>
<li>Solidion Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sti#NASDAQ">STI</a>) dipped 33.5% to $0.83 in pre-market trading. Solidion Technology priced its $3.85 million private placement.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 32.4% to $0.2178 in pre-market trading. Fisker is preparing for a possible bankruptcy filing, The Wall Street Journal reported, citing sources.</li>
<li>Hello Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/momo#NASDAQ">MOMO</a>) fell 19.1% to $6.21 pre-market trading after the company reported fourth-quarter financial results and issued first-quarter revenue guidance.</li>
<li>Erayak Power Solution Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/raya#NASDAQ">RAYA</a>) fell 19.1% to $0.76 in pre-market trading after surging 31% on Wednesday.</li>
<li>Pagaya Technologies Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgy#NASDAQ">PGY</a>) declined 14.1% to $13.32 in pre-market trading after the company commenced an underwritten offering of 6.5 million shares.</li>
<li>Futu Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/futu#NASDAQ">FUTU</a>) shares fell 11.5% to $57.90 in pre-market trading following fourth-quarter results.</li>
<li>Global Gas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hgas#NASDAQ">HGAS</a>) shares fell 10.3% to $2.27 in pre-market trading after surging 16% on Wednesday.</li>
<li>Vroom, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrm#NASDAQ">VRM</a>) shares tumbled 9.4% to $15.85 as the company reported a loss of $80.51 per share for the fourth quarter. The company&rsquo;s quarterly sales came in at $235.92 million which beat the analyst consensus estimate of $232 million.</li>
<li>Qilian International Holding Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qli#NASDAQ">QLI</a>) shares tumbled 9.2% to $0.5905 in pre-market trading after surging 18% on Wednesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37682741/dollar-general-adobe-and-3-stocks-to-watch-heading-into-thursday"> Dollar General, Adobe And 3 Stocks To Watch Heading Into Thursday</a>

WIIM

Spero Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported its Q4 earnings results on Wednesday, March 13, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Spero Therapeutics beat estimated earnings by 1060.0%, reporting an EPS of $0.96 versus an estimate of $-0.1.
Revenue was up $26.08 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.03 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.34</td>
<td>-0.33</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.23</td>
<td>-0.25</td>
<td>0.55</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>14.97M</td>
<td>1.07M</td>
<td>1.00M</td>
<td>22.87M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>25.47M</td>
<td>2.72M</td>
<td>2.07M</td>
<td>47.44M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Spero Therapeutics <a href="https://www.benzinga.com/quote/SPRO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Recap: Spero Therapeutics Q4 Earnings

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $(0.10) by 1060 percent. This is a 74.55 percent increase over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $73.524 million which beat the analyst consensus estimate of $18.633 million by 294.58 percent. This is a 54.98 percent increase over sales of $47.441 million the same period last year.

Earnings Beats

Spero Therapeutics Q4 2023 GAAP EPS $0.96 Beats $(0.10) Estimate, Sales $73.524M Beat $18.633M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
&bull; Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) is expected to report earnings for its fourth quarter.
&bull; Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) is likely to report earnings for its first quarter.
&bull; Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $22.50 million.
&bull; Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) is estimated to report quarterly earnings at $2.65 per share on revenue of $8.67 billion.
&bull; Magic Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGIC#NASDAQ">MGIC</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $117.50 million.
&bull; Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $1.62 billion.
&bull; iShares $ Corp Bond UCITS ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $4.73 million.
&bull; Aadi Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AADI#NASDAQ">AADI</a>) is estimated to report quarterly loss at $0.65 per share on revenue of $6.29 million.
&bull; Moolec Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) is likely to report quarterly loss at $0.07 per share on revenue of $600 thousand.
&bull; ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is likely to report quarterly loss at $0.50 per share on revenue of $15.33 million.
&bull; Target Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TH#NASDAQ">TH</a>) is expected to report quarterly earnings at $0.24 per share on revenue of $118.00 million.
&bull; iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) is expected to report quarterly loss at $0.24 per share on revenue of $3.04 million.
&bull; WideOpenWest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOW#NYSE">WOW</a>) is projected to report quarterly loss at $0.01 per share on revenue of $170.57 million.
&bull; Tuniu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) is estimated to report earnings for its fourth quarter.
&bull; Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is expected to report quarterly earnings at $0.31 per share on revenue of $1.15 billion.
&bull; ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is estimated to report quarterly loss at $1.29 per share on revenue of $1.28 billion.
&bull; ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $594.97 million.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is likely to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is likely to report quarterly loss at $0.02 per share on revenue of $69.79 million.
&bull; Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $136.05 million.
&bull; Global Indemnity Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBLI#NYSE">GBLI</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $141.00 million.
<h3>Companies Reporting After The Bell</h3>
&bull; i-80 Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IAUX#AMEX">IAUX</a>) is estimated to report earnings for its fourth quarter.
&bull; RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.62 per share on revenue of $72.29 million.
&bull; Adams Resources &amp; Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AE#AMEX">AE</a>) is projected to report quarterly loss at $0.08 per share on revenue of $678.36 million.
&bull; Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is projected to report quarterly loss at $0.12 per share on revenue of $96.40 million.
&bull; Profire Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFIE#NASDAQ">PFIE</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $14.61 million.
&bull; Jowell Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JWEL#NASDAQ">JWEL</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $228.53 million.
&bull; MorphoSys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOR#NASDAQ">MOR</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $67.89 million.
&bull; North American (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOA#NYSE">NOA</a>) is likely to report quarterly earnings at $0.74 per share on revenue of $248.81 million.
&bull; Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is expected to report quarterly earnings at $0.34 per share on revenue of $140.16 million.
&bull; Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter.
&bull; VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is estimated to report quarterly earnings at $0.12 per share on revenue of $129.06 million.
&bull; SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) is projected to report quarterly loss at $0.14 per share on revenue of $1.10 million.
&bull; scPharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCPH#NASDAQ">SCPH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $5.52 million.
&bull; NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $1.19 million.
&bull; Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is projected to report quarterly earnings at $0.29 per share on revenue of $199.20 million.
&bull; Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is projected to report quarterly loss at $0.10 per share on revenue of $18.63 million.
&bull; Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter.
&bull; electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is likely to report quarterly loss at $0.61 per share on revenue of $4.97 million.
&bull; OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $88.52 million.
&bull; Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) is estimated to report quarterly earnings at $0.40 per share on revenue of $129.37 million.
&bull; Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) is estimated to report quarterly earnings at $2.20 per share on revenue of $7.39 billion.
&bull; Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $142.86 million.
&bull; Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEAR#NASDAQ">HEAR</a>) is estimated to report quarterly earnings at $0.60 per share on revenue of $111.60 million.
&bull; Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) is likely to report quarterly loss at $0.44 per share on revenue of $17.68 million.
&bull; Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $130.76 million.
&bull; GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is likely to report quarterly loss at $0.13 per share on revenue of $45.52 million.
&bull; Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly loss at $0.26 per share on revenue of $41.40 million.
&bull; FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $23.12 million.
&bull; BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $75.05 million.
&bull; Boxlight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) is expected to report quarterly loss at $0.63 per share on revenue of $36.55 million.
&bull; SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is projected to report quarterly loss at $0.04 per share on revenue of $169.53 million.
&bull; Gold Resource (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GORO#AMEX">GORO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $18.95 million.
&bull; Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.50 per share on revenue of $5.00 million.
&bull; KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $6.94 million.
&bull; Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is likely to report quarterly earnings at $0.79 per share on revenue of $19.04 million.
&bull; ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) is likely to report quarterly loss at $0.11 per share on revenue of $3.54 million.
&bull; UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $383.83 million.
&bull; Vroom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRM#NASDAQ">VRM</a>) is projected to report quarterly loss at $29.60 per share on revenue of $232.00 million.
&bull; Ocean Power Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#AMEX">OPTT</a>) is projected to report earnings for its third quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AADI

ACDC

ADCT

ANIK

ARCO

BGSF

BOXL

CHRS

DLTR

ECOR

FOSL

FTCI

GBLI

GORO

GRWG

HLTH

HNRG

IAUX

ISPC

JWEL

KRMD

LQDA

LRFC

MGIC

MLEC

Morgan Stanley Capital Protected Notes for S&P 500 Index

NVGS

OPAL

OPTT

PESI

PFIE

PTMN

QNRX

SCPH

SGMO

SHCR

SSSS

TOUR

Earnings Scheduled For March 13, 2024

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-13. Here's what investors need to know before the announcement.
Analysts estimate that Spero Therapeutics will report an earnings per share (EPS) of $-0.10. 
Spero Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.03, which was followed by a 1.8% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.03</td>
<td>-0.34</td>
<td>-0.33</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.23</td>
<td>-0.25</td>
<td>0.55</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710262884_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Spero Therapeutics were trading at $1.74 as of March 11. Over the last 52-week period, shares are up 15.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SPRO/earnings">To track all earnings releases for Spero Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Spero Therapeutics

Biotech

General

Spero Therapeutics Announces Clearance Of IND For SPR206 To Treat MDR Gram-Negative Bacterial Infections

Spero Therapeutics Expects To Provide Phase 2a Topline Proof Of Concept Data From SPR720 Program; Co. Also Initiated Dosing In PIVOT-PO Phase 3 Trial And Is Entitled To Receive $95M In Milestones As Part Of License Agreement

Spero Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, announced today the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). Spero is entitled to receive $95 million in development milestone payments from GSK, which is payable in four equal installments over two years.
"First patient visit, in the PIVOT-PO Phase 3 clinical trial, is an important milestone in our tebipenem HBr program," said Sath Shukla, President and CEO of Spero Therapeutics. "We are developing Tebipenem HBr to potentially be the first oral broad-spectrum carbapenem in the U.S. for use in patients with cUTI. Oral administration may provide physicians with an alternative to hospital-based IV therapy, for appropriate patients, with potential value to the broader healthcare system."
PIVOT-PO is a global, randomized, double-blind, pivotal Phase 3 clinical trial of oral tebipenem HBr vs. IV imipenem cilastatin, in hospitalized adult patients with cUTI/AP. Patients are being randomized 1:1 to receive tebipenem HBr (600&nbsp;mg) orally every six hours, or imipenem cilastatin (500&nbsp;mg) IV every six hours, for a total of seven to ten days. The primary efficacy endpoint will be overall response (composite of clinical cure plus microbiological eradication) at the test-of-cure visit. The primary analysis for the trial will be an assessment of non-inferiority (NI) in the microbiological intention-to-treat population, based on a 10% NI margin. The trial is designed to enroll approximately 2,648 patients, with randomization stratified by age, baseline diagnosis (cUTI or AP), and the presence or absence of urinary tract instrumentation. For further details on the trial, refer to clinicaltrials.gov identifier <a href="https://www.globenewswire.com/Tracker?data=wImGZesXfZ2Tg5FKW-YEEu5ZiXvffH7efVHd9RfS-o1TYQhS4b4wN1ojrTx6jsvMnWnUqX06l3-XDxTX5IwGkw1xsV-qJABRzpEAl9WzLmx94lt5AzcGAtBVO0Sb-5-Smg67n5QhaARYALj9CFECnw==">NCT06059846</a>.
The FDA has indicated that positive and persuasive results from PIVOT-PO, supported with confirmatory evidence of efficacy, could be sufficient to support approval of tebipenem HBr as a treatment for cUTI, including pyelonephritis, for a limited use indication.
Under the terms of its license agreement with GSK, Spero is also eligible to receive the following milestone/royalty payments: (1) an additional $25 million in development milestones; (2) up to $150 million in potential commercial milestones based on first commercial sale; (3) up to $225 million in potential sales-based milestones; and (4) low-single digit to low-double digit tiered royalties on net product sales of tebipenem HBr in all territories, except Japan and certain other Asian countries. Additional information on the license agreement is available <a href="https://www.globenewswire.com/Tracker?data=RUchagS-xzeGJ_8tV2oPSH5mkaQ4MTHW3GRgbKsZGAyUHrR2qChJZek4As4AxsHF9CdGu9z1Re-wzA9hH0ZT6rLszEvgeGZ5m0uEcJ57iI5AnxflxGcu44Bbjn4bURLl">here</a>.
About Tebipenem HBr
Tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994) is Spero's novel late-stage development asset, an oral formulation of tebipenem pivoxil, a carbapenem antibiotic of the β-lactam class marketed by&nbsp;Meiji Seika Pharma Co. Ltd. (Meiji) in&nbsp;Japan&nbsp;as Orapenem&#xAE;&nbsp;since 2009 for pediatric infections limited to pneumonia, otitis media and sinusitis. Carbapenems are an important subclass of antibiotics because they have been observed to be safe and effective in the treatment of drug-resistant Gram-negative bacterial infections.&nbsp;Tebipenem HBr is being developed for the treatment of complicated urinary tract infections, including AP, caused by certain microorganisms. If approved, tebipenem HBr may be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the&nbsp;US Food and Drug Administration (FDA)&nbsp;for the treatment of cUTI and AP.
Tebipenem HBr Research Support
Select tebipenem HBr studies have been funded in part with federal funds from the&nbsp;U.S. Department of Health and Human Services;&nbsp;Administration for Strategic Preparedness and Response;&nbsp;Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

Spero Therapeutics Announces First Patient, First Visit For Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr In Complicated Urinary Tract Infections; Spero Is Entitled To Receive $95M In Development Milestone Payments From GSK Over 2 Years

<h3>Understanding Value Stocks</h3>
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. 
<h2>Below is a list of notable value stocks in the healthcare sector:</h2>
<ol>
<li>Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) - P/E: 7.31</li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) - P/E: 1.0</li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) - P/E: 3.0</li>
<li>Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) - P/E: 6.62</li>
<li>Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) - P/E: 2.83</li>
</ol>
This quarter, Cross Country Healthcare experienced a decrease in earnings per share, which was $0.69 in Q2 and is now $0.39. Prenetics Global saw an increase in earnings per share from -0.75 in Q2 to $-0.05 now. Its most recent dividend yield is at 1.99%, which has decreased by 0.02% from 2.01% in the previous quarter.
Spero Therapeutics saw an increase in earnings per share from -0.23 in Q2 to $-0.06 now. Most recently, Arcturus Therapeutics reported earnings per share at $-0.61, whereas in Q2 earnings per share sat at $-1.98. Most recently, Zymeworks reported earnings per share at $-0.38, whereas in Q2 earnings per share sat at $-0.75. 
The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

ARCT

CCRN

ZYME

5 Value Stocks In The Healthcare Sector

<h3>Gainers</h3>
<ul>
<li>Theseus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRX#NASDAQ">THRX</a>) stock increased by 34.1% to $2.87 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 142.2K shares, which is 116.8 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $125.1 million. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) stock increased by 19.87% to $2.05. Today's trading volume for this security ended up closing at 123.2K shares, which is 17.2 percent of its average volume over the last 100 days. The company's market cap stands at $2.0 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock moved upwards by 17.94% to $0.55. Trading volume for this security closed at 1.5 million, accounting for 1128.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.2 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares rose 9.58% to $1.6. The market value of their outstanding shares is at $26.9 million. The company's, Q3 earnings came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares increased by 9.41% to $0.93. The company's market cap stands at $45.3 million. As per the news, the Q1 earnings report came out today. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock increased by 8.1% to $1.2. The market value of their outstanding shares is at $63.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) stock decreased by 22.1% to $10.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 179.7K shares, which is 34.7 percent of its average volume over the last 100 days. The company's market cap stands at $351.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>Tenax Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENX#NASDAQ">TENX</a>) stock fell 15.89% to $0.52. Today's trading volume for this security ended up closing at 22.1 million shares, which is 4198.0 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $12.4 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock declined by 13.8% to $1.75. This security traded at a volume of 87.4K shares come close, making up 25.7% of its average volume over the last 100 days. The company's market cap stands at $55.4 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) shares fell 12.55% to $5.63. The market value of their outstanding shares is at $47.7 million. The company's, Q3 earnings came out yesterday. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 10.15% to $0.19. Today's trading volume for this security ended up closing at 1.7 million shares, which is 84.6 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $5.9 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock declined by 9.8% to $0.5. The market value of their outstanding shares is at $5.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

HROW

OWLT

PXMD

RNLX

TENX

THRX

XAIR

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock moved upwards by 15.8% to $0.54 during Monday's after-market session. This security traded at a volume of 1.4 million shares come close, making up 1011.8% of its average volume over the last 100 days. The company's market cap stands at $3.2 million. </li>
<li>Kronos Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRON#NASDAQ">KRON</a>) stock rose 8.33% to $0.81. The company's market cap stands at $47.3 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares increased by 7.08% to $0.33. The market value of their outstanding shares is at $4.7 million. The company's, Q3 earnings came out 2 days ago. </li>
<li>Azenta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) shares increased by 6.67% to $51.0. Azenta's trading volume hit 76.4K shares by close, accounting for 10.8% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.0 billion. The company's, Q4 earnings came out today. </li>
<li>PaxMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXMD#NASDAQ">PXMD</a>) shares increased by 6.43% to $1.82. This security traded at a volume of 58.1K shares come close, making up 8.1% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 million. </li>
<li>Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) stock increased by 6.3% to $1.18. The market value of their outstanding shares is at $62.2 million. As per the news, the Q3 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares decreased by 23.9% to $9.76 during Monday's after-market session. This security traded at a volume of 164.8K shares come close, making up 31.8% of its average volume over the last 100 days. The company's market cap stands at $342.7 million. As per the press release, Q3 earnings came out today. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 13.8% to $1.75. Today's trading volume for this security ended up closing at 67.1K shares, which is 19.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $55.4 million. As per the press release, Q2 earnings came out today. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares fell 12.45% to $0.38. This security traded at a volume of 158.6K shares come close, making up 6.6% of its average volume over the last 100 days. The company's market cap stands at $16.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares declined by 9.8% to $0.5. The market value of their outstanding shares is at $5.9 million. </li>
<li>Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) stock declined by 9.48% to $5.83. The market value of their outstanding shares is at $49.4 million. The company's, Q3 earnings came out today. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 8.22% to $3.13. The company's market cap stands at $13.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTA

HEPA

KRON

MNPR

SNTI

12 Health Care Stocks Moving In Monday's After-Market Session

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported its Q3 earnings results on Monday, November 13, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Spero Therapeutics missed estimated earnings by 100.0%, reporting an EPS of $-0.06 versus an estimate of $-0.03.
Revenue was up $23.47 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.11 which was followed by a 3.45% drop in the share price the next day.
Here's a look at Spero Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.34</td>
<td>-0.33</td>
<td>0.04</td>
<td>-0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.23</td>
<td>-0.25</td>
<td>0.55</td>
<td>-0.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.07M</td>
<td>1.00M</td>
<td>22.87M</td>
<td>5.42M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>2.72M</td>
<td>2.07M</td>
<td>47.44M</td>
<td>2.01M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Spero Therapeutics <a href="https://www.benzinga.com/quote/SPRO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Spero Therapeutics Q3 Earnings

Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is a 81.82 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $25.47 million which beat the analyst consensus estimate of $14.97 million by 70.16 percent. This is a 1.17K percent increase over sales of $2.01 million the same period last year.

Spero Therapeutics Q3 EPS $(0.06) Misses $(0.03) Estimate, Sales $25.47M Beat $14.97M Estimate